A study in the Journal of Translational Medicine reported that fratricide‑driven, unedited CD7 CAR‑T cells produced anti‑leukemic activity in preclinical models of T‑cell leukemia. The approach leverages selective loss of CD7‑expressing CAR‑T cells during manufacturing to avoid gene editing while preserving potency against malignant T cells. The unedited strategy could reduce manufacturing complexity and regulatory burden versus gene‑edited CAR‑T products, but will require close evaluation of on‑target, off‑tumor toxicity and persistence in human trials. Sponsors should plan for clinical safety monitoring of T‑cell aplasia and infectious complications.